Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23961000 | 0.88 | ALDH1A1 (0.66) | ALDH1A1TDP1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL24596998 | 0.87 | ALDH1A1 (0.49) | ALDH1A1TDP1SMN1; SMN2TSHRSIGMAR1 | |
| SCHEMBL15354487 | 0.87 | ALDH1A1 (0.49) | ALDH1A1TDP1SMN1; SMN2TSHRSIGMAR1 | |
| SCHEMBL18545126 | 0.80 | ALDH1A1 (0.43) | ALDH1A1TDP1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL7127556 | 0.78 | ALDH1A1 (0.51) | ALDH1A1TDP1SMN1; SMN2TSHRSIGMAR1 | |
| SCHEMBL26889455 | 0.76 | ALDH1A1 (0.51) | ALDH1A1TDP1SMN1; SMN2TSHRSIGMAR1 | |
| SCHEMBL17971051 | 0.76 | ALDH1A1 (0.50) | ALDH1A1TDP1SMN1; SMN2SIGMAR1MEN1 | |
| SCHEMBL17289089 | 0.76 | ALDH1A1 (0.53) | ALDH1A1TDP1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL20071542 | 0.76 | ALDH1A1 (0.67) | ALDH1A1TDP1SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL13864818 | 0.75 | ALDH1A1 (0.57) | ALDH1A1TDP1TSHRSIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | ENDOCYTE, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20200405760-A1 | COMPOSITIONS AND METHODS FOR CAR T CELL THERAPY | ENDOCYTE, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | CD47, PBK, GZMB | ALDH1A1 4160/4885TDP1 989/4885SMN1; SMN2 582/4885 |
| US-20200405760-A1 | COMPOSITIONS AND METHODS FOR CAR T CELL THERAPY | CD47, PBK, GZMB | ALDH1A1 4160/4885TDP1 989/4885SMN1; SMN2 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.